× Key messages Background DAPA-HF update Conclusions Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Background

What do we already know about this topic?

  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of a first hospitalization for heart failure (HHF).
  • DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; NCT03036124) was designed to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular (CV) death in patients with chronic heart failure with reduced ejection fraction (HFrEF).
  • Initial results from the study published in 2019 indicated that the risk of worsening heart failure or death from CV causes was lower among patients with HFrEF who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes.1